The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

New research reveals that prion disease mutations can alter the structure of neuron synapses long before symptoms emerge.

Century Therapeutics Inc (IPSC) stock saw a modest uptick, ending the day at $1.7 which represents a slight increase of $0.00 or 0.00% from the prior close of $1.7. The stock opened at $1.68 and ...

CAMBRIDGE, England, September 30, 2024--bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces its comprehensive program for ...

PSC-derived cells and micro-physiological systems provide significant advancements in enhancing neuronal disease models, ...

More than 1,000 people have marched on the US Consulate in Belfast for an Ireland Palestine Solidarity Campaign (IPSC) ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Optimizing iPSC differentiation significantly improves in vitro Alzheimer's disease models, leading to more accurate and ...

研究团队首次成功建立了大熊猫iPSC重编程方法，将从大熊猫身上提取的普通皮肤细胞（皮肤成纤维细胞）重编程为 干细胞 ...

Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief ...

IHI Power Services Corp. (IPSC), a leading provider of asset management, operations and maintenance (O&M), remote operations ...